Betrixaban
💊 Brand Formulations & Prices
2 brands sorted by unit price
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesBetriXa is indicated for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness and at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
The recommended dose of Betrixaban is an initial single dose of 160 mg, followed by 80 mg once daily. Daily oral doses should be given at the same time of day with food. The recommended duration of treatment is 35 to 42 days.
Betrixaban is contraindicated in patients with active pathological bleeding. It is also contraindicated in patients with severe hypersensitivity reaction to Betrixaban
Most common adverse reaction is bleeding, epidural or spinal hematoma may develop during spinal/epidural anesthesia or puncture.
Risk of Bleeding
: Can cause bleeding. Promptly evaluate any signs or symptoms of blood loss.
Spinal/Epidural Anesthesia or Puncture
: When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis. Do not remove an epidural catheter earlier than 72 hours after the last administration of BetriXa. Do not administer the next BetriXa dose earlier than 5 hours after the removal of the catheter. If traumatic puncture occurs, delay the administration of BetriXa for 72 hours.
Severe Renal Impairment
: Increase risk of bleeding events.
Concomitant P-gp Inhibitors
: Increase risk of bleeding events.
Betrixaban is a factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require a cofactor (such as Anti-thrombin III) for activity. Betrixaban inhibits free factor Xa and prothrombinase activity. By directly inhibiting factor Xa, Betrixaban decreases thrombin generation (TG). Betrixaban has no direct effect on platelet aggregation.